SCHEMBL9950849

SCHEMBL9950849

CCCC(Nc1ccc(C(=O)NCCC(=O)OC)cn1)c1cnc(-c2ccc(C(F)(F)F)cc2)nc1

nearest known ligand 0.68

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GCGR P47871 14/20 0.68
GCG P01275 8/20 0.58
GLP1R P43220 2/20 0.48
GIPR P48546 2/20 0.48
MTTP P55157 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10263286 1.00 GCGR (0.68) GCGRGCGGLP1RGIPRMTTP
SCHEMBL10262991 1.00 GCGR (0.68) GCGRGCGGLP1RGIPRMTTP
SCHEMBL10283436 0.93 GCGR (0.62) GCGRGCGGLP1RGIPRMTTP
SCHEMBL9951040 0.91 GCGR (0.81) GCGRGCGGLP1RGIPR
SCHEMBL9951549 0.91 GCGR (0.81) GCGRGCGGLP1RGIPR
SCHEMBL9950897 0.91 GCGR (0.81) GCGRGCGGLP1RGIPR
SCHEMBL27932692 0.88 GCGR (0.73) GCGRGCGGLP1RGIPRMTTP
SCHEMBL9951358 0.86 GCGR (0.58) GCGRGCGGLP1RGIPR
SCHEMBL10263033 0.86 GCGR (0.56) GCGRGCGGLP1RGIPRMTTP
SCHEMBL9951042 0.84 GCGR (0.56) GCGRGCGGLP1RGIPRMTTP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 US disclosed
US-8933104-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-01-13 US disclosed
US-20140329862-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2014-11-06 US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 US disclosed
EP-2655331-A1 GLUCAGON RECEPTOR MODULATORS Pfizer Inc (US) 2013-10-30 EP disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329862-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 GCGR 2/4885GCG 15/4885GLP1R 1/4885
US-20150094338-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 GCGR 2/4885GCG 15/4885GLP1R 1/4885
US-20120165343-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 GCGR 2/4885GCG 15/4885GLP1R 1/4885
US-20150266861-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 GCGR 2/4885GCG 15/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.